We are monitoring the impact of COVID-19 & Recession alarm on APAC Companion Diagnostics Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Companion Diagnostics Market Research Report – Segmented By Indication, Technology and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 591
Pages: 140

APAC Companion Diagnostics Market Size (2022 to 2027)

As per our report, the Asia Pacific Companion Diagnostics Market size was worth USD 0.79 billion in 2022. This value is further estimated to be growing at a CAGR of 24.73% from 2022 to 2027 and worth USD 2.37 billion by 2027.

APAC was the fastest-growing regional market in 2020 in the global market due to the growing number of clinical trials for cancer and government support for new drug discovery in the pharmaceutical industry. In addition, growth in the region is favored by increasing population, increased spending on healthcare R&D by the government, and a growing base of the affluent middle-class population.

Companion diagnostics have accompanied the development of personalized medicine, an advanced approach in the clinical treatment process. Companion diagnostics are diagnostic tests used to improve the effectiveness of the drug and pre-determining the treatment's efficacy. These products are mainly in-vitro devices or imaging tools, either developed after the drug is in the market or during drug development. Benefits provided by these products are providing crucial information on an individual’s risk factors for chronic conditions and enables health care professionals to decide whether drugs it more beneficial over their risks or not.

The companion diagnostics market's key factors are accelerated drug regulatory approvals, merging new pharmaceuticals and diagnostics, improved efficacy profile of drugs, and reduced healthcare expenditure.

Complex clinical trial procedures are hindering the market growth.

This research report on the APAC Companion Diagnostics Market has been segmented and sub-segmented into the following categories:

By Indications:

  • Oncology
    • Colorectal Cancer
    • Lung Cancer
    • Breast Cancer
    • Gastric Cancer
    • Melanoma
  • Inflammation and Autoimmune Diseases
  • Cardiovascular Diseases
  • Central Nervous System Disorders
  • Virology Diseases

By Technology:

  • Immunohistochemistry
  • Molecular Diagnostics
    • In-Situ Hybridization
    • Real-Time PCR
    • Gene Sequencing

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, the rapid increase in population in developing countries like China and India is the fastest-growing market in APAC.

The Indian companion diagnostics market is predicted to showcase a healthy CAGR during the forecast period due to the Indian government's support for In-vitro Diagnostics (IVD) system for patients’ treatment. In addition, public and private partnerships and the launch of innovative schemes to improve Indian IVD technology are majorly propelling the market's demand. 

The Chinese Companion Diagnostics Market is forecasted to be the fastest-growing regional market in the APAC region during the forecast period. China has the fastest growth in the APAC market due to the increasing population, demand for personalized medical care, and cancer diseases. Growing cancer, neurological and cardiovascular diseases are driving the companion diagnostics market. Also, China is recording 20% of lung cancer deaths from the past few years. Recently, the US food and drug administration approved new PD-L 1 companion diagnostics that help to treat metastasis cancer effectively.

The Japanese Companion Diagnostics Market is estimated to be another lucrative regional market in the APAC region. This is because the ministry of health labor welfare has implemented similar regulations as per the FDA. Furthermore, constant economic growth is also one of the factors for the market to grow in this country. In addition, increasing population and changes in lifestyle are greatly influencing the demand of the market. 

KEY MARKET PLAYERS:

A few of the major companies operating in the APAC Companion Diagnostics Market profiled in this report are Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc., Biogenex Laboratories Inc., Ventana Medical Systems Inc., and Thermo Fisher Scientific Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Indications                            

                                5.1.1 Oncology 

                                                5.1.1.1 Colorectal Cancer

                                                5.1.1.2 Breast Cancer

                                                5.1.1.3 Lung Cancer

                                                5.1.1.4 Gastric Cancer

                                                5.1.1.5 Melanoma

                                5.1.2 Inflammation and Autoimmune Diseases  

                                5.1.3 Cardiovascular Diseases    

                                5.1.4 Central Nervous System Disorders               

                                5.1.5 Virology Diseases 

                5.2 By Technology                           

                                5.2.1 Immuno Histochemistry    

                                5.2.2 Molecular Diagnostics        

                                                5.2.2.1 In-Situ Hybridization

                                                5.2.2.2 Real Time PCR

                                                5.2.2.3 Gene Sequencing

6. Geographical Analysis                                              

                6.3 Asia-Pacific                 

                                6.1 Introduction               

                                6.2 China             

                                6.3 India              

                                6.4 Japan            

                                6.5 South Korea               

                                6.6 Australia      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Abbott Molecular Inc.                            

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues             

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 Roche Molecular Systems Inc.                            

                8.3 Leica Biosystems Nussloch GmbH                     

                8.4 BioMérieux Inc.                        

                8.5 Dako Inc.                     

                8.6 Qiagen Ltd.                 

                8.7 ARUP Laboratories                  

                8.8 Myriad Genetics Inc.                              

                8.9 Biogenex Laboratories, Inc.                 

                8.10 Ventana Medical Systems Inc.                         

                8.11 Thermo Fisher Scientific Inc.                             

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Expert Opinions                                        

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Asia-Pacific Companion Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Oncology Market By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Inflammation and Autoimmune Diseases Market By Region, From 2022 - 2027 (USD Billion)
  5. Asia-Pacific Cardiovascular Diseases Market By Region, From 2022 - 2027 (USD Billion)
  6. Asia-Pacific Central Nervous System Disorders Market By Region, From 2022 - 2027 (USD Billion)
  7. Asia-Pacific Virology Diseases Market By Region, From 2022 - 2027 (USD Billion)
  8. Asia-Pacific Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  9. Asia-Pacific Immuno Histochemistry Market By Region, From 2022 - 2027 (USD Billion)
  10. Asia-Pacific Molecular Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  11. Asia-Pacific Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  12. Asia-Pacific Colorectal Cancer Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  13. Asia-Pacific Breast Cancer Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  14. Asia-Pacific Lung Cancer Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  15. Asia-Pacific Gastric Cancer Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  16. Asia-Pacific Melanoma Diagnostics Market By Region, From 2022 - 2027 (USD Billion)
  17. Asia-Pacific Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  18. Asia-Pacific In-Situ Hybridization Market By Region, From 2022 - 2027 (USD Billion)
  19. Asia-Pacific Real Time PCR Market By Region, From 2022 - 2027 (USD Billion)
  20. Asia-Pacific Gene Sequencing Market By Region, From 2022 - 2027 (USD Billion)
  21. China Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  22. China Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  23. China Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  24. China Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  25. India Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  26. India Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  27. India Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  28. India Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  29. Japan Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  30. Japan Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  31. Japan Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  32. Japan Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  33. South Korea Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  34. South Korea Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  35. South Korea Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  36. South Korea Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  37. Australia Companion Diagnostics Market By Indication, From 2022 - 2027 (USD Billion)
  38. Australia Companion Diagnostics Market By Technology, From 2022 - 2027 (USD Billion)
  39. Australia Oncology Diagnostics Market By Type, From 2022 - 2027 (USD Billion)
  40. Australia Molecular Diagnostics Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample